Skip to main content

CellSafe Inks Distribution Deal for Molecular Coronavirus Test

NEW YORK — South Korean diagnostics firm CellSafe said on Wednesday that has signed a distribution agreement with Hong Kong-based Dynasty Castle Investments for CellSafe's LAMPlex RT-qLAMP COVID-19 Detection Assay.

Under the terms of the deal, Dynasty Castle Investments will have the right to sell the test in Portugal and six unspecified African countries in partnership with its local distributors. Additional terms were not disclosed.

According to CellSafe, the test uses real-time reverse transcription loop-mediated isothermal amplification to detect the SARS-CoV-2 N gene in nasopharyngeal swab, oropharyngeal swab, and sputum samples. It provides results within 25 minutes and runs on most PCR machines, the company said.